# Recombinant Human Papillomavirus Nonavalent Vaccine in Preventing Human Papilloma Virus in Younger Healthy Participants

> **NCT02568566** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **National Cancer Institute (NCI)** · enrollment: 201 (actual)

## Conditions studied

- Human Papillomavirus-Related Carcinoma

## Interventions

- **OTHER:** Laboratory Biomarker Analysis
- **BIOLOGICAL:** Recombinant Human Papillomavirus Nonavalent Vaccine

## Key facts

- **NCT ID:** NCT02568566
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2016-05-19
- **Primary completion:** 2020-02-06
- **Final completion:** 2027-01-10
- **Target enrollment:** 201 (ACTUAL)
- **Last updated:** 2026-04-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02568566

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02568566, "Recombinant Human Papillomavirus Nonavalent Vaccine in Preventing Human Papilloma Virus in Younger Healthy Participants". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT02568566. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*